The goal is to have a vaccine by 2025 that is 80% effective and lasts for at least four years.
A new vaccine trial is underway in Africa in an attempt to control malaria, a disease that not only kills 1 million people every year, but also makes 300 million seriously sick. If the trial results come back positive, a worldwide vaccine could be available as soon as 2012.
Los Angeles Times:
Each year, malaria kills more than 1 million people—90% of them in sub-Saharan Africa and 80% of them younger than 5—and makes 300 million people seriously ill. Major progress in controlling the disease has been made by the widespread adoption of bed nets to keep mosquitoes from attacking children at night and by the use of artemisinin-based therapy, which is the most effective treatment for infections.
But vaccines have historically proved the best technique for controlling infectious diseases, and researchers have high hopes for a new one called RTS,S/AS2A, or Mosquirix.
A massive trial of it is underway in Africa, with 5,000 children already enrolled. If results are favorable, marketing approval could be sought as soon as 2012, making it the first commercial vaccine available for the disease, researchers said this week in announcing the trial at the Multilateral Initiative on Malaria Pan-African Malaria Conference in Nairobi, Kenya.